Manufacturer
50 recalls in our database name Ascend Laboratories, LLC as the manufacturing or recalling firm.
Of the 50 recalls from Ascend Laboratories, LLC we have scored against our rubric, 0 (0%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 2 (4%) are Severe.
The manufacturer string comes from the agency’s own source notice — for FDA recalls, the “recalling firm” field; for NHTSA recalls, the vehicle manufacturer; for CPSC recalls, the firm-of-record on the joint press release. A single corporate family can appear under multiple manufacturer strings as agency notices aren’t standardized on a canonical name. If you don’t see recalls you expect, try a parent-company search or a broader full-text search.
Severity scores below are computed from the agency’s classification and the recall text, never from manufacturer behaviour or history. Many manufacturers issue routine corrective actions (software updates, labelling corrections) that are correctly scored low — having recalls on this list isn’t inherently a quality signal.
Ascend Laboratories is recalling 2,652 bottles of Fingolimod capsules nationwide because they failed to meet dissolution specifications, potentially affecting medication effectiveness.
Ascend Laboratories is recalling 135 bottles of Aripiprazole 20 mg tablets nationwide due to failure of spectroscopic identification testing, indicating the product may not meet established quality standards.
Ascend Laboratories is recalling 12,804 bottles of Dabigatran Etexilate 150mg capsules nationwide due to detection of N-nitroso-dabigatran (NDAB) impurity levels above the Acceptable Daily Intake limit caused by manufacturing process deviations.
Ascend Laboratories is recalling 13,560 bottles of Dabigatran Etexilate 75 mg capsules nationwide because testing detected N-nitroso-dabigatran impurity levels above acceptable limits. The issue stems from a manufacturing quality control deviation.
Ascend Laboratories is recalling 2,628 bottles of Metoprolol Succinate Extended-Release Tablets (50 mg) nationwide due to failed dissolution specification. The tablets may not dissolve properly, preventing proper medication absorption.
Ascend Laboratories recalls 49,632 bottles of Metoprolol Succinate extended-release tablets (25 mg) nationwide and in Puerto Rico due to failure to meet dissolution specifications that could reduce drug effectiveness.
Ascend Laboratories is recalling 6,336 bottles of Metoprolol Succinate Extended-Release Tablets, 50 mg, distributed nationwide and in Puerto Rico, due to failed dissolution specification.
Ascend Laboratories is recalling Rasagiline Mesylate Tablets 1 mg due to black spots and metallic specks on tablets. The recall affects 12,192 bottles distributed to customers in 19 states and Puerto Rico.
Ascend Laboratories is recalling Metoprolol Succinate Extended-Release Tablets 25 mg nationwide because the tablets failed to meet dissolution specifications, which may affect how the medication releases in the body.
Ascend Laboratories recalls Cefixime 400 mg capsules due to failed impurities and degradation specifications. The affected 42,698 bottles were distributed nationwide.
Ascend Laboratories LLC is recalling Cefixime Capsules 400 mg nationwide due to failed impurities and degradation specifications. The affected lot is Lot 20140282 with an expiration date of December 2021.
Ascend Laboratories LLC is recalling 34,296 bottles of Olmesartan Medoxomil 20 mg tablets because they may contain a foreign tablet or capsule.
Ascend Laboratories is recalling Cephalexin for Oral Suspension because unidentified impurities were found at higher levels than allowed.
Ascend Laboratories LLC is recalling Cephalexin for Oral Suspension due to CGMP deviations involving unidentified impurities.
Ascend Laboratories is recalling Cephalexin for Oral Suspension because unidentified impurities were found in specific lots.
Ascend Laboratories is recalling Cephalexin for Oral Suspension because it failed impurity and degradation specifications.
Ascend Laboratories is recalling Cephalexin for Oral Suspension because it failed impurity and degradation specifications. The recall covers 9,524 bottles distributed nationwide.
Ascend Laboratories LLC is recalling 1,200 bottles of Tizanidine 4mg tablets distributed in Michigan due to failed dissolution specifications.
Ascend Laboratories is recalling 192 bottles of Olmesartan Medoxomil 20 mg tablets because they were released in error with an alternate API source before approval.
Ascend Laboratories is recalling Minocycline Hydrochloride Extended-Release Tablets due to low dissolution test results.
Ascend Laboratories is recalling Atorvastatin Calcium 80 mg tablets because they failed dissolution specifications. The product was distributed to wholesalers nationwide.
Ascend Laboratories is recalling 3,072 bottles of Tamsulosin Hydrochloride 0.4 mg capsules because stability testing revealed high out-of-specification dissolution results.
Ascend Laboratories is recalling Quetiapine 400 mg tablets because a metal shard was found in a tablet. Patients should stop using the affected lot and contact their healthcare provider.
Ascend Laboratories is recalling 10 mg Amlodipine Besylate tablets because 2.5 mg tablets were found mixed in the bottles.
Ascend Laboratories LLC is recalling 1,739 bottles of Metformin Hydrochloride 500 mg tablets because Amlodipine tablets were found in the packaging.